Cantor Fitzgerald set a $25.00 price target on Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) in a report issued on Tuesday, December 26th. The firm currently has a buy rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Valeant Pharmaceuticals Intl’s FY2018 earnings at $2.96 EPS.
Other analysts also recently issued reports about the stock. Mizuho increased their price objective on shares of Valeant Pharmaceuticals Intl from $7.00 to $10.00 and gave the company an underperform rating in a research report on Friday, December 15th. Piper Jaffray Companies reaffirmed a sell rating and set a $14.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Sunday, September 17th. Canaccord Genuity reaffirmed a hold rating and set a $16.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Tuesday, October 3rd. HC Wainwright reaffirmed a hold rating and set a $17.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Monday, September 18th. Finally, Vetr raised shares of Valeant Pharmaceuticals Intl from a strong sell rating to a sell rating and set a $12.46 price target on the stock in a report on Thursday, September 28th. Six equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Valeant Pharmaceuticals Intl presently has a consensus rating of Hold and an average target price of $18.20.
Shares of Valeant Pharmaceuticals Intl (VRX) opened at $23.84 on Tuesday. Valeant Pharmaceuticals Intl has a 1 year low of $8.31 and a 1 year high of $24.43. The company has a market cap of $8,300.00, a PE ratio of 6.11, a P/E/G ratio of 0.72 and a beta of -0.22. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26.
In other Valeant Pharmaceuticals Intl news, Director John Paulson bought 344,216 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The stock was purchased at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the completion of the acquisition, the director now owns 94,559 shares in the company, valued at approximately $1,361,649.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 5.87% of the company’s stock.
Several hedge funds have recently bought and sold shares of the stock. Paulson & CO. Inc. grew its holdings in shares of Valeant Pharmaceuticals Intl by 12.5% in the second quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after purchasing an additional 2,428,900 shares in the last quarter. Vanguard Group Inc. boosted its stake in Valeant Pharmaceuticals Intl by 4.2% during the second quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock worth $125,853,000 after buying an additional 294,643 shares during the period. Dimensional Fund Advisors LP boosted its stake in Valeant Pharmaceuticals Intl by 327.6% during the third quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock worth $64,086,000 after buying an additional 3,426,410 shares during the period. CIBC World Markets Inc. boosted its stake in Valeant Pharmaceuticals Intl by 2.3% during the second quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock worth $64,726,000 after buying an additional 83,592 shares during the period. Finally, Chou Associates Management Inc. boosted its stake in Valeant Pharmaceuticals Intl by 29.7% during the second quarter. Chou Associates Management Inc. now owns 3,053,843 shares of the specialty pharmaceutical company’s stock worth $53,030,000 after buying an additional 700,000 shares during the period. 49.45% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://ledgergazette.com/2018/01/13/cantor-fitzgerald-reiterates-25-00-price-target-for-valeant-pharmaceuticals-intl-vrx.html.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.